Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ
2005

Selective Estrogen Receptor Modulators and Breast Cancer Prevention

Sample size: 25 publication 10 minutes Evidence: moderate

Author Information

Author(s): Namba Ruri, Young Lawrence JT, Maglione Jeannie E, McGoldrick Erik T, Liu Stephenie, Wurz Gregory T, DeGregorio Michael W, Borowsky Alexander D, MacLeod Carol L, Cardiff Robert D, Gregg Jeffrey P

Primary Institution: University of California, Davis

Hypothesis

Can selective estrogen receptor modulators inhibit the growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ?

Conclusion

Tamoxifen and ospemifene inhibit the growth of premalignant mammary lesions and the progression to invasive carcinoma in a transplantable mouse model of DCIS.

Supporting Evidence

  • The MIN-O was ER-positive and ovarian ablation resulted in reduced MIN-O growth and tumor development.
  • Tamoxifen and ospemifene treatments decreased the MIN growth and tumor incidence in comparison with the control.
  • Both SERMs significantly decreased cell proliferation.

Takeaway

This study shows that two medications, tamoxifen and ospemifene, can help stop early breast cancer from getting worse in mice.

Methodology

The study used a mouse transplantation model of ductal carcinoma in situ to assess the effects of tamoxifen and ospemifene on tumor growth and incidence.

Limitations

The study is limited to a mouse model, which may not fully replicate human breast cancer behavior.

Participant Demographics

Three-week-old female FVB/J mice were used in the study.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1186/bcr1317

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication